English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Summary   Aims  This open‐label prospective phase I/ II a clinical study used autologous bone marrow‐derived mesenchymal stromal cells ( BM ‐ MSC s) followed by mesenchymal stromal cells conditioned media ( MSC ‐ CM ) for the first time to treat multiple sclerosis ( MS ) patients. The primary goal was to assess the safety and feasibility and the secondary was efficacy. The correlation between the  MSC ‐ CM  content and treatment outcome was investigated.    Methods  Ten  MS  patients who failed conventional therapy were enrolled. Adverse events were recorded to assess safety. The Expanded Disability Status Scale ( EDSS ) was the primary efficacy measurement, the secondary included clinical (25 WFT , 9‐ PHT ), cognitive ( MMS ), ophthalmology ( OCT ,  VEP ), and radiological ( MRI  lesion and volume) tests. The  MSC s‐ CM  concentration of 27 inflammatory biomarkers was investigated.    Results  The treatment protocol was well tolerated by patients. There was an overall trend of improvement in all the tests, except the lesion volume which increased significantly. A decrease of 4 and 3.5 points on the  EDSS  was achieved in two patients. We report a correlation between a decreased lesion number at baseline and higher  IL ‐6,  IL ‐8, and  VEGF MSC ‐ CM  content.    Conclusion  The used protocol was safe and feasible with possible efficacy. The addition of  MSC ‐ CM  could be related to the magnitude of  EDSS  improvement observed.

cns neuroscience and therapeutics

Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: Clinical, ophthalmological and radiological assessments of safety and efficacy